Barinthus Biotherapeutics plc. (BRNS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-6M 0 6M 12M 18M Q1 '20: 705K Q2 '20: 511K Q3 '20: 3.3M Q4 '20: 354K Q1 '21: 215K Q2 '21: 35K Q3 '21: 19K Q4 '21: -1K Q1 '22: 15M Q2 '22: 17.1M Q3 '22: 6.2M Q4 '22: 6.5M Q1 '23: 468K Q2 '23: 334K Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 15M Q4 '24: 0 Q3 '25: 0 Q4 '25: 0 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q4 '25

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-27M -18M -9M 0 9M 18M 27M Q1 '20: -4.6M Q2 '20: -4.3M Q3 '20: -1.4M Q4 '20: -9.6M Q1 '21: -6.2M Q2 '21: -16.8M Q3 '21: -5.5M Q4 '21: -16.7M Q1 '22: 654K Q2 '22: 13.2M Q3 '22: 7.2M Q1 '23: -21.5M Q2 '23: -26.3M Q3 '23: -16.1M Q4 '23: -20M Q1 '24: -16.9M Q2 '24: -18.3M Q3 '24: -9.4M Q4 '24: -23.4M Q1 '25: -20.6M Q2 '25: -23.3M Q3 '25: -15.1M Q4 '25: -11.6M Q1 '26: -6.1M Q2 '26: -11M Q1 '20 Q1 '21 Q1 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-27M -18M -9M 0 9M 18M 27M Q1 '20: -3.8M Q2 '20: -3.6M Q3 '20: 158K Q4 '20: -10.5M Q1 '21: -15.3M Q2 '21: -15.9M Q3 '21: -4.6M Q4 '21: -15.1M Q1 '22: 2.6M Q2 '22: 15.7M Q3 '22: 8.2M Q1 '23: -18.2M Q2 '23: -23.8M Q3 '23: -14.1M Q4 '23: -17.3M Q1 '24: -15.5M Q2 '24: -16.9M Q3 '24: -8.1M Q4 '24: -20.5M Q1 '25: -19.6M Q2 '25: -21.1M Q3 '25: -14.6M Q4 '25: -11.1M Q1 '26: -5.5M Q2 '26: -10.6M Q1 '20 Q1 '21 Q1 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q1 '20: -4.3M Q2 '20: -950K Q3 '20: -861K Q4 '20: -4.9M Q1 '21: -8M Q2 '21: -14.6M Q3 '21: -2M Q4 '21: -8M Q1 '22: -6.6M Q2 '22: -8.4M Q3 '22: 11.9M Q4 '22: -11.3M Q1 '23: -3.2M Q2 '23: -17M Q3 '23: -11.2M Q4 '23: -19.6M Q1 '24: -11.8M Q2 '24: -12M Q3 '24: -18.2M Q4 '24: 13.1M Q1 '25: -14.9M Q2 '25: -18.1M Q3 '25: -10.7M Q4 '25: -4.2M Q1 '26: -3.4M Q2 '26: -8.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q1 '20: -4.3M Q2 '20: -996K Q3 '20: -891K Q4 '20: -5.1M Q1 '21: -8.4M Q2 '21: -14.8M Q3 '21: -2.1M Q4 '21: -8.4M Q1 '22: -7.7M Q2 '22: -10.4M Q3 '22: 9.5M Q4 '22: -11.9M Q1 '23: -5.7M Q2 '23: -20M Q3 '23: -11.2M Q4 '23: -19.8M Q1 '24: -12.1M Q2 '24: -12.2M Q3 '24: -18.3M Q4 '24: 12.8M Q1 '25: -14.9M Q2 '25: -18.1M Q3 '25: -10.7M Q4 '25: -4.2M Q1 '26: -3.4M Q2 '26: -8.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q3 '20: 15.9M Q1 '21: 8.1M Q2 '21: 24.9M Q3 '21: 34.8M Q1 '22: 38.3M Q2 '22: 38.2M Q3 '22: 38.2M Q1 '23: 38M Q2 '23: 38.4M Q3 '23: 38.5M Q1 '24: 38.8M Q2 '24: 39M Q3 '24: 39.4M Q1 '25: 40.3M Q2 '25: 40.3M Q3 '25: 40.7M Q1 '26: 40.8M Q2 '26: 40.8M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '20: -2.25 Q1 '21: -3.66 Q2 '21: -3.85 Q3 '21: -3.99 Q4 '21: -3.05 Q1 '22: -1.08 Q2 '22: -0.03 Q3 '22: 0.32 Q4 '23: -1.92 Q1 '24: -1.84 Q2 '24: -1.65 Q3 '24: -1.49 Q4 '24: -1.55 Q1 '25: -1.64 Q2 '25: -1.73 Q3 '25: -1.88 Q4 '25: -1.64 Q1 '26: -1.29 Q2 '26: -1.03 Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.